Genovis
23,75
SEK
+0,85 %
1.647 følger denne virksomhed
GENO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+0,85%
+27,01%
-2,66%
-3,85%
+7,47%
-16,67%
-48,26%
+6,03%
-13,25%
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Læs mereMarkedsværdi
1,55 mia. SEK
Aktieomsætning
788,36 t SEK
Omsætning
130,36 mio.
EBIT %
35,08 %
P/E
47,5
Udbytteafkast, %
-
Finanskalender
21.5
2025
Delårsrapport Q1'25
21.5
2025
Generalforsamling '25
12.8
2025
Delårsrapport Q2'25
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
NOTICE OF ANNUAL GENERAL MEETING OF GENOVIS AB (PUBL)
Redeye: Genovis Q4 2024 - Solid but softer than we estimated
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools